135906-03-5

Basic information

• Product Name: Endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane dihydrochloride
• Synonyms: Endo-3-Amine -9-Methyl-9-Azabicyclo[3,3,1]Nonane Dihydrochloride;ENDO-3-AMINE -9-METHYL-9-AZABICYCLO3,3,1NONANE 2HCL;Endo-3-amino-9-methyl-9-azabicyclo[3,3,1]nonanedihydrochloride;endo-9-Methyl-9-azabicyclo[3.3.1]nonan-3-aMine Dihydrochloride;9-Azabicyclo[3.3.1]nonan-3-amine,9-methyl-,hydrochloride(1:2),(3-endo)-
• CAS NO: 135906-03-5
• Molecular Formula: C9H18N2.2ClH
• Molecular Weight: 227.177
• EINECS: 1592732-453-0
• Mol File: 135906-03-5.mol

Chemical Properties

• Boiling Point: 294.6 °C at 760 mmHg
• Flash Point: 132 °C
• Appearance: /
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: Endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane dihydrochloride(135906-03-5)
• EPA Substance Registry System: Endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane dihydrochloride(135906-03-5)

Safety Data

• Hazardous Substances Data: 135906-03-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane dihydrochloride is used as an impurity in the synthesis of Granisetron HCl for its role as an antiemetic agent. This application is due to the compound's involvement in the production process of Granisetron HCl, which is a medication that helps prevent nausea and vomiting, particularly in patients undergoing chemotherapy, radiation therapy, or surgery.

Upstream product

• 1006601-11-1 tert-butyl 9-methyl-9-azabicyclo[3.3.1]nonan-3-ylcarbamate 
• 111-30-8 Glutaraldehyde 
• 552-70-5 pseudopelletierine 
• 6164-67-6 9-methyl-9-aza-bicyclo[3.3.1 ]nonan-3-one oxime 

Relevant articles and documents

Preparation method of granisetron intermediate

The invention discloses a preparation method of a granisetron intermediate. The preparation method comprises the following steps: step 1, carrying out a Mannich reaction on acetone dicarboxylic acid represented by a formula III to obtain pseudopelletierine represented by a formula IV; step 2, carrying out a reaction on the pseudopelletierine and hydroxylamine to prepare 3-pseudopelletierine oximerepresented by a formula V; and step 3, carrying out preparation by adopting one of the following schemes: (1) carrying out catalytic reduction on the 3-pseudopelletierine oxime through sodium bis(2-methoxyethoxy)aluminumhydride and Lewis acid to obtain a crude product of endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane represented by a formula I, and directly using the crude product of endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane to prepare granisetron, or purifying the crude product of endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane for preparing granisetron; and (2) carrying out catalytichydrogenation reduction on the 3-pseudopelletierine oxime through Raney nickel to obtain a mixture of endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane, purifying the mixture to obtain endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane represented by the formula I, and using the endo-3-amine-9-methyl-9-azabicyclo[3,3,1]nonane used for preparing granisetron. The method has the advantages of mild reaction conditions, high reaction yield and low cost, and is suitable for industrial production.

Benzoxazole carboxamides for treating CINV and IBS-D

Compounds of formulae I and II: are disclosed as 5-HT3 inhibitors. Those compounds that exhibit central activity are useful in treating CINV; those that inhibit peripheral receptors are useful to treat IBS-D.